1700632060
[10] Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science, 2002, 295(5562)
:2097-2100.
1700632061
1700632062
[11] Ruggeri L, Mancusi A, Burchielli E, et al. Natural killer cell alloreactivity in allogeneic hematopoietic transplantation. Curr Opin Oncol, 2007, 19(2)
:142-147.
1700632063
1700632064
[12] Storb RF, Champlin R, Riddell SR, et al. Non-myeloablative transplants for malignant disease. Hematology Am Soc Hematol Educ Program, 2001, 375-391.
1700632065
1700632066
[13] Mielcarek M, Storer BE, Sandmaier BM, et al. Comparable outcomes after non-myeloablative hematopoietic cell transplantation with unrelated and related donors. Biol Blood Marrow Transplant, 2007, 13(12)
:1499-1507.
1700632067
1700632068
[14] Sorror ML, Storer BE, Maloney DG, et al. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood, 2008, 111(1)
:446-452.
1700632069
1700632070
[15] Gratwohl A, Brand R, Apperley J, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant, 2006, 37(5)
:439-449.
1700632071
1700632072
[16] Kumar P, Defor TE, Brunstein C, et al. Allogeneic hematopoietic stem cell transplantation in adult acute lymphocytic leukemia: impact of donor source on survival. Biol Blood Marrow Transplant, 2008, 14(12)
:1394-1400.
1700632073
1700632074
[17] Gratwohl A, Brand R, Apperley J, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation（EBMT). Haematologica, 2006, 91(4)
:513-521.
1700632075
1700632076
[18] Morris ES, Hill GR. Advances in the understanding of acute graft-versus-host disease. Br J Haematol, 2007, 137(1)
:3-19.
1700632077
1700632078
[19] Messina C, Faraci M, de Fazio V, et al. Prevention and treatment of acute GvHD. Bone Marrow Transplant, 2008, Suppl 2
:S65-70.
1700632079
1700632080
[20] Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase Ⅱ study. Lancet, 2008, 371(9624)
:1579-1586.
1700632081
1700632082
[21] Kotloff RM, Ahya VN, Crawford SW. Pulmonary Complications of Solid Organ and Hematopoietic Stem Cell Transplantation. Am J Respir Crit Care Med, 2004, 70(1)
:22-48.
1700632083
1700632084
[22] 徐志松，周建英，黄河．异基因骨髓移植后不同时期感染并发症的临床研究．中华血液学杂志，2004，25(8)
:496-498.
1700632085
1700632086
[23] Kenneth V, Rolston I. The infectious diseases society of america 2002 Guidelines for the use of antimicrobial agents in patients with cancer and neutropenia: salient features and comments. Clin Infect Dis, 2004, 39(Suppl 1)
:44-48.
1700632087
1700632088
[24] Ortega M, Rovira M, Almela M, et al. Bacterial and fungal bloodstream isolates from 796 hematopoietic stem cell transplant recipients between 1991 and 2000. Ann Hematol, 2005, 84(1)
:40-46.
1700632089
1700632090
[25] Karthaus M, Cornely OA. Recent developments in the management of invasive fungal infections in patients with hematological malignancies. Ann Hematol, 2005, 84(4)
:207-216.
1700632091
1700632092
[26] 中华内科杂志编辑委员会．血液病／恶性肿瘤患者侵袭性真菌感染的诊断标准与治疗原则（修订版）．中华内科杂志，2007，46(7)
:607-610.
1700632093
1700632094
[27] Gentile G, Picardi A, Capobianchi A, et al. A prospective study comparing quantitative Cytomegalovirus（CMV）polymerase chain reaction in plasma and pp65 antigenemia assay in monitoring patients after allogeneic stem cell transplantation. BMC Infect Dis, 2006, 6
:167.
1700632095
1700632096
[28] Stewart S. Pulmonary infections in transplantation pathology. Arch Pathol Lab Med, 2007, 131(8)
:1219-1231.
1700632097
1700632098
[29] Porter D, Levine JE. Graft-versus-host disease and graft-versus-leukemia after donor leukocyte infusion. Semin Hematol, 2006, 43(1)
:53-61.
1700632099
1700632100
[30] Schmid C, Labopin M, Nagler A, et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol, 2007, 25(31)
:4938-4945.
1700632101
1700632102
[31] Fowler DH. Shared biology of GVHD and GVT effects: potential methods of separation. Crit Rev Oncol Hematol, 2006, 57(3)
:225-244.
1700632103
1700632104
[32] Rezvani AR, Storb RF. Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation. J Autoimmun, 2008, 30(3)
:172-179.
1700632105
1700632106
（黄 河）
1700632107
1700632108
1700632109
[
上一页 ]
[ :1.70063206e+09 ]
[
下一页 ]